Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06003348 · ClinicalTrials.gov registry record · Phase 4
Hydroxycitrate: A Novel Therapy for Calcium Phosphate Urinary Stones
A Phase 4 study of Calcium Phosphate Kidney Stones, sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT06003348 is a Phase 4 study of Calcium Phosphate Kidney Stones that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 25 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06003348, a Phase 4 study of Calcium Phosphate Kidney Stones, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This study tests whether hydroxycitrate, a molecule closely related to citrate, can reduce calcium phosphate stone recurrence.
Conditions Studied
Interventions
- DRUG Placebo
- DIETARY_SUPPLEMENT OHCit- standard dose
- DRUG Potassium Citrate
- DIETARY_SUPPLEMENT OHCit- low dose
Study Locations (1)
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-12-13 |
| Est. Completion | 2028-08-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06003348
The ClinicalTrials.gov registry entry for NCT06003348 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Calcium Phosphate Kidney Stones appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT06003348 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06003348 about?
NCT06003348 is a clinical study titled "Hydroxycitrate: A Novel Therapy for Calcium Phosphate Urinary Stones". This study tests whether hydroxycitrate, a molecule closely related to citrate, can reduce calcium phosphate stone recurrence.
What is the current status of trial NCT06003348?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2023-12-13. Estimated completion is 2028-08-31.
What conditions does trial NCT06003348 study?
This clinical trial studies the following conditions: Calcium Phosphate Kidney Stones.
What interventions are being tested in trial NCT06003348?
The interventions under investigation include: Placebo (DRUG), OHCit- standard dose (DIETARY_SUPPLEMENT), Potassium Citrate (DRUG), OHCit- low dose (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06003348?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06003348 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.